Stories of putting people at the centre
Accessed: 20.11.2019
2020 is a critical year for our Joint Programme as we collectively define the path to getting back on track to ending the AIDS epidemic by 2030. Our revised timelines for adoption of the next strategy are highly ambitious. We need the full support of all the tremendously dedicated people in UNAIDS-w
...
ithin our staff, our board and all our stakeholders to make this happen.
more
В настоящем отчете (это уже четвертое его издание) анализируются препятствия и факторы, затрудняющие доступ к препаратам для лечения лекарственно-устойчивого туб
...
ркулеза, в том числе новым и применяющимся по новым показаниям.
more
UNAIDS/99.31E (English original, June 1999)
1st revision, April 2000
Compiled by Tin Geber for HIVOS. London, March 2018
Report of Meeting: 4 November 2014, Roma
Supplement October 2010
HIV/AIDS, security and conflict: making the connections
Regional Operational Plan 2016 FY17 Strategic Direction Summary
2 May 2016
Updated on 6 APRIL 2020
There are serious concerns that the situation might escalate in the next weeks modelling the epi curve of other regions. The interlinkages between human mobility and the current pandemic of COVID-19 are well established, and while international flights have been suspended i
...
n the region, the porous borders on land and water crossings remain difficult to control.
more
Washington, D.C., ÉUA, du 26 au 30 septembre 2016
Point 4.10 de l’ordre du jour provisoire
CD55/14 8 juillet 2016
Original : anglais
Washington, D.C., EUA, del 26 al 30 de septiembre del 2016
Punto 4.10 del orden del día provisional
CD55/14 8 de julio del 2016
Original: inglés
Learning from earthquake relief and recovery operations
The Antimicrobial Resistance Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics. Although we can see progress — it’s hanging by a thread.
We have reac
...
hed a tipping point where large and prominent drugmakers have retreated from the antibiotics field and smaller innovative biotech companies have gone bankrupt due to the poor financial rewards on offer.
more